Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 876

1.
2.

Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.

Waller CF, Ranganna GM, Pennella EJ, Blakeley C, Bronchud MH, Mattano LA Jr, Berzoy O, Voitko N, Shparyk Y, Lytvyn I, Rusyn A, Popov V, Láng I, Beckmann K, Sharma R, Baczkowski M, Kothekar M, Barve A.

Ann Hematol. 2019 May;98(5):1217-1224. doi: 10.1007/s00277-019-03639-5. Epub 2019 Mar 1.

3.
4.

Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study).

Wolff T, Schulz H, Losem C, Reichert D, Hurtz HJ, Sandner R, Harde J, Grebhardt S, Potthoff K, Mueller U, Fietz T.

Eur J Haematol. 2019 Feb;102(2):174-181. doi: 10.1111/ejh.13189. Epub 2018 Nov 23.

PMID:
30347466
5.

The effect of pegylated granulocyte colony-stimulating factor on collateral function and myocardial ischaemia in chronic coronary artery disease: A randomized controlled trial.

Traupe T, Stoller M, Gloekler S, Meier P, Seiler C.

Eur J Clin Invest. 2019 Jan;49(1):e13035. doi: 10.1111/eci.13035. Epub 2018 Nov 6.

PMID:
30316200
6.

A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma.

Fuchida SI, Sunami K, Matsumoto M, Okumura H, Murayama T, Miyamoto T, Otsuka E, Fujishima N, Izumi T, Tamaki S, Hiramatsu Y, Kuroda Y, Shimazaki C, Akashi K, Harada M; Japan Study Group for Cell Therapy and Transplantation (JSCT).

Int J Hematol. 2019 Jan;109(1):107-114. doi: 10.1007/s12185-018-2543-y. Epub 2018 Oct 4. Erratum in: Int J Hematol. 2018 Nov 7;:.

PMID:
30284685
7.

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers.

Choi C, Yoo BW, Kim CO, Hong T, Jin BH, Seo KS, Jang JY, Park MS.

Drug Des Devel Ther. 2018 Aug 1;12:2381-2387. doi: 10.2147/DDDT.S158277. eCollection 2018.

8.

Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC).

Clemons M, Mazzarello S, Hilton J, Joy A, Price-Hiller J, Zhu X, Verma S, Kehoe A, Ibrahim MF, Sienkiewicz M, Stober C, Vandermeer L, Hutton B, Mallick R, Fergusson D.

Support Care Cancer. 2019 Apr;27(4):1345-1354. doi: 10.1007/s00520-018-4408-6. Epub 2018 Aug 11.

PMID:
30099602
9.

Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study.

Matsue K, Kumagai K, Sugiura I, Ishikawa T, Igarashi T, Sato T, Uchiyama M, Miyamoto T, Ono T, Ueda Y, Kiguchi T, Sunaga Y, Sasaki T, Suzuki K.

Int J Hematol. 2018 Nov;108(5):524-534. doi: 10.1007/s12185-018-2505-4. Epub 2018 Jul 24. Erratum in: Int J Hematol. 2018 Aug 30;:.

PMID:
30043330
10.

Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors.

Iwasa S, Yamamoto N, Shitara K, Tamura K, Matsubara N, Tajimi M, Lin AB, Asou H, Cai Z, Inoue K, Shibasaki Y, Saito K, Takai H, Doi T.

Cancer Sci. 2018 Oct;109(10):3216-3223. doi: 10.1111/cas.13750.

11.

Filgrastim following HLA-Identical Allogeneic Bone Marrow Transplantation: Long-Term Outcomes of a Randomized Trial.

Ben Othman T, Ghedira H, Ben Abdejlil N, Lakhal A, Torjemane L, Ben Hamed L, Hamida S, Zouari B, Ladeb S.

Biol Blood Marrow Transplant. 2018 Dec;24(12):2459-2465. doi: 10.1016/j.bbmt.2018.07.024. Epub 2018 Jul 21.

PMID:
30036571
12.

Pharmacokinetic and pharmacodynamic bioequivalence study of a pegfilgrastim biosimilar INTP5 in healthy subjects.

Singh I, Patel A, Patel R, Jose V.

Cancer Chemother Pharmacol. 2018 Aug;82(2):329-337. doi: 10.1007/s00280-018-3620-x. Epub 2018 Jun 15.

PMID:
29948023
13.

A Randomized, Single-Blind Study Evaluating the Effect of a Bone Pain Education Video on Reported Bone Pain in Patients with Breast Cancer Receiving Chemotherapy and Pegfilgrastim.

Guinigundo AS, Maxwell CL, Vanni L, Morrow PK, Reiner M, Shih A, Klippel Z, Blanchard E.

Pain Manag Nurs. 2018 Dec;19(6):693-706. doi: 10.1016/j.pmn.2018.04.002. Epub 2018 Jun 21.

PMID:
29935909
14.

Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.

Iyer G, Balar AV, Milowsky MI, Bochner BH, Dalbagni G, Donat SM, Herr HW, Huang WC, Taneja SS, Woods M, Ostrovnaya I, Al-Ahmadie H, Arcila ME, Riches JC, Meier A, Bourque C, Shady M, Won H, Rose TL, Kim WY, Kania BE, Boyd ME, Cipolla CK, Regazzi AM, Delbeau D, McCoy AS, Vargas HA, Berger MF, Solit DB, Rosenberg JE, Bajorin DF.

J Clin Oncol. 2018 Jul 1;36(19):1949-1956. doi: 10.1200/JCO.2017.75.0158. Epub 2018 May 9.

15.

Vinorelbine-Cyclophosphamide compared to cyclophosphamide in peripheral blood stem cell mobilization for multiple myeloma.

de Mel S, Chen Y, Lin A, Soh TG, Ooi M, Yap ES, Donato LKS, Halim NAA, Mah J, Lim K, Poon LM, Tan B, Yelly, Lim HL, Koh LP, Tai BC, Chen Z, Chng WJ, Gopalakrishnan SK, Tan LK.

Hematol Oncol Stem Cell Ther. 2018 Dec;11(4):225-232. doi: 10.1016/j.hemonc.2018.04.001. Epub 2018 Apr 23.

16.

A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.

Waller CF, Tiessen RG, Lawrence TE, Shaw A, Liu MS, Sharma R, Baczkowski M, Kothekar MA, Micales CE, Barve A, Ranganna GM, Pennella EJ.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1087-1095. doi: 10.1007/s00432-018-2643-3. Epub 2018 Apr 18.

PMID:
29671069
17.

Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial.

Miyake O, Murata K, Tanaka S, Ishiguro H, Toi M, Tamura K, Kawakami K.

Jpn J Clin Oncol. 2018 May 1;48(5):410-416. doi: 10.1093/jjco/hyy030.

PMID:
29590407
18.

An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.

Vacirca JL, Chan A, Mezei K, Adoo CS, Pápai Z, McGregor K, Okera M, Horváth Z, Landherr L, Hanslik J, Hager SJ, Ibrahim EN, Rostom M, Bhat G, Choi MR, Reddy G, Tedesco KL, Agajanian R, Láng I, Schwartzberg LS.

Cancer Med. 2018 May;7(5):1660-1669. doi: 10.1002/cam4.1388. Epub 2018 Mar 23.

19.

Adjuvant continuous metronomic adriamycin + cyclophosphamide followed by weekly nab-paclitaxel for high-risk early-stage breast cancer.

Cho E, Wu Q, Rubinstein L, Linden H, Gralow J, Specht J, Gadi V, Ellis G.

Breast J. 2018 Jul;24(4):610-614. doi: 10.1111/tbj.13013. Epub 2018 Mar 13.

20.

Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium.

Spigel DR, Hainsworth JD, Shipley DL, Mekhail TM, Zubkus JD, Waterhouse DM, Daniel DB, Burris HA 3rd, Greco FA.

Lung Cancer. 2018 Mar;117:38-43. doi: 10.1016/j.lungcan.2018.01.007. Epub 2018 Jan 12.

PMID:
29496254

Supplemental Content

Loading ...
Support Center